{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:29:25Z","timestamp":1763000965434,"version":"3.45.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["18CDA34110361"],"award-info":[{"award-number":["18CDA34110361"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ahjo.2021.100049","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T19:21:39Z","timestamp":1633634499000},"page":"100049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Adverse cardiovascular events in patients treated with mogamulizumab"],"prefix":"10.1016","volume":"9","author":[{"given":"Jennifer M.","family":"Kwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana L.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirstin","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine","family":"Foss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren A.","family":"Baldassarre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ahjo.2021.100049_bb0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/jcpt.12124","article-title":"Incidence and risk-factors of CHOP\/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma","volume":"39","author":"Limat","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.ahjo.2021.100049_bb0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/annonc\/mdg070","article-title":"Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma","volume":"14","author":"Limat","year":"2003","journal-title":"Ann. Oncol."},{"issue":"85","key":"10.1016\/j.ahjo.2021.100049_bb0015","first-page":"367","article-title":"Novel targeted therapies in peripheral T cell lymphoma","volume":"15","author":"Jagadeesh","year":"2013","journal-title":"Discov. Med."},{"issue":"9","key":"10.1016\/j.ahjo.2021.100049_bb0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/cancers10090339","article-title":"Current immunotherapeutic approaches in T cell non-Hodgkin lymphomas","volume":"10","author":"Poggio","year":"2018","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ahjo.2021.100049_bb0025","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"year":"2018","series-title":"Immunotherapy Emerges as Treatment for T-Cell Lymphoma. ASCO-SITC Clinical Immuno-Oncology Symposium","author":"Gorshein","key":"10.1016\/j.ahjo.2021.100049_bb0030"},{"key":"10.1016\/j.ahjo.2021.100049_bb0035","first-page":"419","article-title":"Marketing approval of mogamulizumab: a triumph for glyco-engineering","volume":"vol. 4, No. 4","author":"Beck","year":"2012"},{"issue":"9","key":"10.1016\/j.ahjo.2021.100049_bb0040","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ahjo.2021.100049_bb0045","first-page":"1085","article-title":"Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma","volume":"12","author":"Ollila","year":"2019","journal-title":"OncoTargetsTher."},{"issue":"1","key":"10.1016\/j.ahjo.2021.100049_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab","volume":"132","author":"Thursky","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.ahjo.2021.100049_bb0055","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/0929867324666170407125017","article-title":"Immune checkpoint inhibitors and cardiac toxicity: an emerging issue","volume":"25","author":"Varricchi","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.ahjo.2021.100049_bb0060","first-page":"6","article-title":"Managing cardiotoxicity associated with immune checkpoint inhibitors","volume":"5","author":"Upadhrasta","year":"2019","journal-title":"Chronic Dis.Transl. Med."},{"issue":"9","key":"10.1016\/j.ahjo.2021.100049_bb0065","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ahjo.2021.100049_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J. Immunother. Cancer"},{"issue":"18","key":"10.1016\/j.ahjo.2021.100049_bb0075","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10124","key":"10.1016\/j.ahjo.2021.100049_bb0080","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ahjo.2021.100049_bb0085","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jaccas.2021.04.001","article-title":"Mogamulizumab-associated acute myocarditis in a patient with t-cell lymphoma","volume":"3","author":"Kwan","year":"2021","journal-title":"JACC Case Rep."},{"issue":"5","key":"10.1016\/j.ahjo.2021.100049_bb0090","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf. J."},{"issue":"5","key":"10.1016\/j.ahjo.2021.100049_bb0095","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/pds.4734","article-title":"Paediatric safety signals identified in VigiBase: methods and results from Uppsala Monitoring Centre","volume":"28","author":"Star","year":"2019","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"3","key":"10.1016\/j.ahjo.2021.100049_bb0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrcardio.2015.169","article-title":"Regulatory T cells in cardiovascular diseases","volume":"13","author":"Meng","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"issue":"6","key":"10.1016\/j.ahjo.2021.100049_bb0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11936-019-0732-5","article-title":"The role of cardiac magnetic resonance imaging to detect cardiac toxicity from cancer therapeutics","volume":"21","author":"Soufer","year":"2019","journal-title":"Curr.Treat. Options Cardiovasc. Med."},{"issue":"3","key":"10.1016\/j.ahjo.2021.100049_bb0110","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic correlates of response to immune checkpoint blockade","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ahjo.2021.100049_bb0115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13073-018-0605-7","article-title":"Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine","volume":"10","author":"Conway","year":"2018","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.ahjo.2021.100049_bb0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40169-019-0225-x","article-title":"The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies","volume":"8","author":"Gong","year":"2019","journal-title":"Clin. Transl. Med."},{"issue":"6371","key":"10.1016\/j.ahjo.2021.100049_bb0125","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602221000471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602221000471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:27:15Z","timestamp":1763000835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602221000471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":25,"alternative-id":["S2666602221000471"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2021.100049","relation":{},"ISSN":["2666-6022"],"issn-type":[{"type":"print","value":"2666-6022"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse cardiovascular events in patients treated with mogamulizumab","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2021.100049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100049"}}